超越强迫症的一线治疗方案。
Moving beyond first-line treatment options for OCD.
作者信息
Paxos Chris
出版信息
Ment Health Clin. 2022 Nov 3;12(5):300-308. doi: 10.9740/mhc.2022.10.300. eCollection 2022 Oct.
Abstract
OCD is characterized by obsessions and compulsions that cause distress, are time-consuming, and interfere with a patient's social, occupational, or other areas of functioning. SSRIs are first-line pharmacologic treatment options and produce response rates of up to 60% in patients with OCD. Several potential strategies have been evaluated for enhancing patient response, including high-dose SSRI therapy, antipsychotic augmentation, and memantine augmentation. Three patient cases are used to explore treatment guidelines, evaluate existing literature, and provide pharmacotherapy recommendations for the management of patients with OCD when first-line therapy fails.
摘要
强迫症的特征是强迫观念和强迫行为，这些会导致痛苦、耗时，并干扰患者的社交、职业或其他功能领域。选择性5-羟色胺再摄取抑制剂（SSRIs）是一线药物治疗选择，在强迫症患者中的有效率高达60%。已经评估了几种增强患者反应的潜在策略，包括高剂量SSRI治疗、抗精神病药物增效和美金刚增效。使用三个患者案例来探索治疗指南、评估现有文献，并为一线治疗失败的强迫症患者管理提供药物治疗建议。
相似文献
1
Moving beyond first-line treatment options for OCD.
Ment Health Clin. 2022 Nov 3;12(5):300-308. doi: 10.9740/mhc.2022.10.300. eCollection 2022 Oct.
2
Obsessive-compulsive disorder.
J Pharm Pract. 2014 Apr;27(2):116-30. doi: 10.1177/0897190014521996. Epub 2014 Feb 27.
3
A benzisothiazole derivative and antipsychotic agent, perospirone, for augmentation of selective serotonin reuptake inhibitors (SSRIs) in refractory obsessive-compulsive disorder (OCD): two patient case series.
Int J Psychiatry Clin Pract. 2006;10(2):142-5. doi: 10.1080/13651500500487586.
4
Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part I: pharmacological treatment.
Braz J Psychiatry. 2023 May 11;45(2):146-161. doi: 10.47626/1516-4446-2022-2891.
5
Agomelatine augmentation of escitalopram therapy in treatment-resistant obsessive-compulsive disorder: a case report.
Case Rep Psychiatry. 2012;2012:642752. doi: 10.1155/2012/642752. Epub 2012 Oct 9.
6
WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults.
CNS Spectr. 2003 Aug;8(8 Suppl 1):7-16. doi: 10.1017/s1092852900006908.
7
Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis.
J Clin Psychiatry. 2016 May;77(5):e605-11. doi: 10.4088/JCP.14r09758.
8
A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
Curr Med Chem. 2018;25(41):5647-5661. doi: 10.2174/0929867325666171222163645.
9
A single-blinded case-control study of memantine in severe obsessive-compulsive disorder.
J Clin Psychopharmacol. 2010 Feb;30(1):34-9. doi: 10.1097/JCP.0b013e3181c856de.
10
[Clinical features of patients with obsessive-compulsive disorder showing different pharmacological responses].
Seishin Shinkeigaku Zasshi. 2006;108(12):1282-92.
引用本文的文献
1
Does early non-improvement predict treatment failure in pharmacotherapy for obsessive-compulsive disorder? A diagnostic test accuracy meta-analysis with individual participant data.
Psychol Med. 2025 Aug 15;55:e237. doi: 10.1017/S0033291725101335.
2
Evaluation of the Relationship Between Disease Severity and Difficulties in Emotion Regulation, Impulsivity, and Quality of Life in Untreated Patients Diagnosed With Obsessive-Compulsive Disorder.
Psychiatry Investig. 2025 Mar;22(3):320-329. doi: 10.30773/pi.2024.0261. Epub 2025 Mar 18.
本文引用的文献
1
Pharmacotherapy for Treatment-Resistant Obsessive-Compulsive Disorder.
J Clin Psychiatry. 2020 Sep 8;81(5):19ac13182. doi: 10.4088/JCP.19ac13182.
2
Augmentation With Memantine in Obsessive-Compulsive Disorder.
J Clin Psychiatry. 2019 Dec 3;80(6):19f13163. doi: 10.4088/JCP.19f13163.
3
Schizophrenia.
N Engl J Med. 2019 Oct 31;381(18):1753-1761. doi: 10.1056/NEJMra1808803.
4
A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder.
Psychiatry Res. 2019 Dec;282:112602. doi: 10.1016/j.psychres.2019.112602. Epub 2019 Oct 4.
5
A systematic review of the use of risperidone, paliperidone and aripiprazole as augmenting agents for obsessive-compulsive disorder.
Expert Opin Pharmacother. 2019 Jan;20(1):47-53. doi: 10.1080/14656566.2018.1540590. Epub 2018 Nov 3.
6
Demystifying serotonin syndrome (or ).
Can Fam Physician. 2018 Oct;64(10):720-727.
7
Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD).
Curr Neuropharmacol. 2019;17(8):710-736. doi: 10.2174/1570159X16666180813155017.
8
Memantine Augmentation Improves Symptoms in Serotonin Reuptake Inhibitor-Refractory Obsessive-Compulsive Disorder: A Randomized Controlled Trial.
Pharmacopsychiatry. 2018 Nov;51(6):263-269. doi: 10.1055/s-0043-120268. Epub 2017 Nov 3.
9
A review of the role of serotonin system genes in obsessive-compulsive disorder.
Neurosci Biobehav Rev. 2017 Sep;80:372-381. doi: 10.1016/j.neubiorev.2017.05.029. Epub 2017 May 30.
10
Memantine as an Adjuvant Treatment for Obsessive Compulsive Symptoms in Manic Phase of Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
J Clin Psychopharmacol. 2017 Apr;37(2):246-249. doi: 10.1097/JCP.0000000000000651.
Zotero 插件